Know Cancer

or
forgot password

PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION


Phase 1
18 Years
N/A
Not Enrolling
Both
Esophageal Cancer, Lung Cancer, Lymphoma

Thank you

Trial Information

PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION


OBJECTIVES:

I. Define the maximum tolerated dose and safety profile of topotecan (TOPO) administered
with daily high-dose thoracic radiotherapy to a total of 60 Gy in patients with solid tumor
or lymphoma.

II. Assess the qualitative and quantitative nature of the toxic effects encountered in this
treatment.

III. Estimate the tissue and tumor TOPO concentrations during radiotherapy by evaluating
plasma TOPO levels.

IV. Evaluate, using Western blot and immunohistochemical stain, the effects of
TOPO/radiotherapy on topoisomerase I levels in peripheral blood lymphocytes (PBL).

V. Determine whether TOPO induces apoptosis in PBL from this patient population.

VI. Examine tumor tissue pre- and post-treatment (if available) for topoisomerase I levels,
DNA damage, topoisomerase I/DNA complexes, and apoptotic events.

OUTLINE:

Radiosensitization plus Radiotherapy. Topotecan, TOPO, NSC-609699; plus external-beam
irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons
acceptable for the boost field).

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Microscopically confirmed solid tumor or lymphoma not potentially curable by
conventional surgery or radiotherapy

- Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60
Gy, including pulmonary and esophageal tumors

- No metastatic disease more effectively treated by systemic chemotherapy

- No history of brain metastases

PATIENT CHARACTERISTICS:

- Age: 18 and over

- Performance status: ECOG 0 or 1

- WBC at least 4,000

- ANC at least 1,500

- Platelets at least 100,000

- Bilirubin no greater than 1.5 mg/dL

- Creatinine no greater than 1.5 mg/dL

- Calcium no greater than 11.0 mg/dL

- No pregnant or nursing women

- Pregnancy test required, as appropriate

- Effective contraception required of fertile patient

PRIOR CONCURRENT THERAPY:

- At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and
recovered

- At least 4 weeks since radiotherapy and recovered

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

George Wilding, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Wisconsin, Madison

Authority:

United States: Food and Drug Administration

Study ID:

CDR0000063990

NCT ID:

NCT00002625

Start Date:

March 1995

Completion Date:

September 2000

Related Keywords:

  • Esophageal Cancer
  • Lung Cancer
  • Lymphoma
  • stage III adult Hodgkin lymphoma
  • stage IV adult Hodgkin lymphoma
  • recurrent non-small cell lung cancer
  • recurrent adult Hodgkin lymphoma
  • recurrent esophageal cancer
  • stage III cutaneous T-cell non-Hodgkin lymphoma
  • stage IV cutaneous T-cell non-Hodgkin lymphoma
  • recurrent cutaneous T-cell non-Hodgkin lymphoma
  • recurrent small cell lung cancer
  • stage III grade 1 follicular lymphoma
  • stage III grade 2 follicular lymphoma
  • stage III grade 3 follicular lymphoma
  • stage III adult diffuse small cleaved cell lymphoma
  • stage III adult diffuse mixed cell lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage III adult immunoblastic large cell lymphoma
  • stage III adult lymphoblastic lymphoma
  • stage III adult Burkitt lymphoma
  • stage IV grade 1 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • stage IV grade 3 follicular lymphoma
  • stage IV adult diffuse small cleaved cell lymphoma
  • stage IV adult diffuse mixed cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • stage IV adult immunoblastic large cell lymphoma
  • stage IV adult lymphoblastic lymphoma
  • stage IV adult Burkitt lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult diffuse large cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • recurrent adult lymphoblastic lymphoma
  • recurrent adult Burkitt lymphoma
  • stage III adult T-cell leukemia/lymphoma
  • stage IV adult T-cell leukemia/lymphoma
  • recurrent adult T-cell leukemia/lymphoma
  • stage III mantle cell lymphoma
  • stage IV mantle cell lymphoma
  • recurrent mantle cell lymphoma
  • recurrent marginal zone lymphoma
  • recurrent small lymphocytic lymphoma
  • stage III small lymphocytic lymphoma
  • stage III marginal zone lymphoma
  • stage IV small lymphocytic lymphoma
  • stage IV marginal zone lymphoma
  • extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  • nodal marginal zone B-cell lymphoma
  • splenic marginal zone lymphoma
  • Esophageal Diseases
  • Esophageal Neoplasms
  • Lung Neoplasms
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Immunoblastic

Name

Location

University of Wisconsin Comprehensive Cancer CenterMadison, Wisconsin  53792